
<div class="card-header d-flex align-items-center p-2 text-white fs-5" >
  <i class="fa-solid fa-flask"></i>
   <h1> ORANGE BOOK >> SITAGLIPTIN PHOSPHATE</h1>
  
    <i class="fa fa-refresh" aria-hidden="true"></i>
  
    <select class="form-select dropdown-width mx-1">
          <option>Select Ingredient</option>
             <option>ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE</option>
            <option>SITAGLIPTIN</option>
            <option>SITAGLIPTIN PHOSPHATE</option>
            <option> METFOMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE</option>
            <option>SIMVASTATIN;SITAGLIPTIN PHOSPHATE</option>
     
    </select>
    
    <select class="form-select dropdown-width mx-1">
      <option>Select RLD</option>
      <option>Yes</option>
    </select>
  
    <select class="form-select dropdown-width mx-1">
      <option>Select Appl Type</option>
      <option>N</option>
    </select>
  
    <select class="form-select dropdown-width mx-1">
      <option>Select Applicant</option>
      <option>MSD SUB MERCK</option>
      <option>ZYDUS LIFESCIENCES</option>
      <option>MERCK SHARP DOHME</option>
      
      

    </select>
  
    <select class="form-select dropdown-width mx-1">
      <option>Select Strength</option>
      <option>15MG;EQ 100MG BASE</option>
      <option>5MG;EQ 100MG BASE</option>
      <option>100MG</option>
      <option>50MG</option>
      <option>25MG</option>
      <option>EQ 25MG BASE</option>
      <option>EQ 50MG BASE</option>
      
      <option>AN EQ 100MG BASE</option>
     
      <option>Z 1GM;EQ 100MG BASE </option>
     
      <option>500MG;EQ 50MG BASE </option>
      
      <option>1GM;EQ 50MG BASE </option>
    
      <option>10MG;EQ 100MG BASE  **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**</option>
      <option>20MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**</option>  
      <option>20MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**</option>
      <option> 40MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**</option>
      <option>40MG;EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** </option>    
      <option>10MG;EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectivenessÂ reasons**</option>
      


    </select>
  </div>
  

  <div class="card body">
    <div class="pb-3 mb-3 px-2 rounded-lg">

      <div class="row">

        <div class="col-xl-4 col-lg-4 col-md-4 col-sm-12">

          <h5>  <span style="color: blue;">1.</span>  GREEN BOOK REGISTRATION NUMBER(GBRN):</h5>
          <p>10083;10313</p>

          <h5>PRODUCT NUMBER:</h5>
          <p>2</p>

          <h5>TRADE NAME:</h5>
          <p>SITAGLIPTIN</p>

          <h5>COMPANY LOGO:</h5>
          <img src="assets/images/components/Merck.png" class="image1">

          <h5>ACTIVE INGREDIENT/COMBITION:</h5>
          <p>ERTUGLIFLOZIN;SITAGLIPTIN PHOSPHATE</p>

          <h5>STRENGTH:</h5>
          <p>15MG;EQ 100MG BASE</p>

          <h5>REFERENCE LISTED DRUG(RLD):</h5>
          <p>Yes</p>

          <h5>REFERENCE STANDARD(RS):</h5>
          <p>Yes</p>

        </div>

        <div class="col-xl-4 col-lg-4 col-md-4 col-sm-12">

          
          <h5>DOSES FORM:</h5>
          <p>TABLET</p>

          <h5>ROUTE:</h5>
          <p>ORAL</p>

          <h5>APPLICANT:</h5>
          <p>MSD SUB MERCK</p>

          <h5>APPLICANT HOLDER FULL NAME:</h5>
          <p>MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC</p>

          <h5>TYPE:</h5>
          <p>Rx</p>
          <img src="assets/images/components/fda.jpg" class="image2">


        </div>

        <div class="col-xl-4 col-lg-4 col-md-4 col-sm-12">

          <h5>APPLICATION NUMBER:</h5>
          <p>209805</p>

          <h5>APPLICATION TYPE:</h5>
          <p>N</p>

          <h5>APPROVAL DATE:</h5>
          <p>19-Dec-2017</p>

        
        </div>

       </div>
      </div>

    </div>
 
    <!-- ==============  Table-Header=========== -->

    <div class="overflow-x-auto ">
      <table class="w-full border border-gray-300">
        <thead class="bg-gray-800 text-white text-xs">
          <tr>
            <th class="px-2 py-1 text-left">Patent No.</th>
            <th class="px-2 py-1 text-left">Patent Claims</th>
            <th class="px-2 py-1 text-left">Product No.</th>
            <th class="px-2 py-1 text-left">Applicant No.</th>
            <th class="px-2 py-1 text-left">Patent Expiration</th>
            <th class="px-2 py-1 text-left">Delist Requested</th>
            <th class="px-2 py-1 text-left">Jarvis RN</th>
            <th class="px-2 py-1 text-left">Drug Substance</th>
            <th class="px-2 py-1 text-left">Drug Product</th>
            <th class="px-2 py-1 text-left">Patent Use Code</th>
            <th class="px-2 py-1 text-left">Submission Date</th>
            <th class="px-2 py-1 text-left">Remarks</th>
            <th class="px-2 py-1 text-left">PDF, CSV, Text File downloadable format</th>
          </tr>
          
        </thead>
    <!-- ==============  Table-Body 1st=========== -->

    <tbody class="bg-yellow-100">
      <tr class="border-b border-gray-300">
        <td class="px-2 py-1 w-1/6">
          <h6 class="text-blue-600 hover:underline"></h6>
          <div class="">
            <p class="text-[#2900FF] font-bold text-sm">US8080580</p>

            <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
              <img src="assets/images/components/espace.png" class="h-1" alt="Google">
            </a>
            <a href="https://patents.google.com/patent/US8080580">
              <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
            </a>

          </div>
        </td>
    
        <td class="px-2 py-1 w-1/6">

          <!-- <button class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">VIEW PATENT CLAIMS</button> -->
           <!-- Button to Open Popup -->
<button (click)="openPopup()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
  VIEW PATENT CLAIMS
</button>

<!-- Popup Modal (Displayed when isPopupOpen = true) -->
<div *ngIf="isPopupOpen" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
  <div class="bg-white p-6 rounded shadow-lg w-96">
    <h2 class="text-lg font-bold">Patent Claims</h2>
    <p class="mt-2">This is a first popup
    </p>
    <!-- Close Button -->
    <button (click)="closePopup()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
  </div>
</div>


        </td>
    
        <td class="px-2 py-1 w-[80px] text-sm">2</td>
        <td class="px-2 py-1 w-[80px] text-sm">209805</td>
        <td class="px-2 py-1 w-[80px] text-sm">13-july-2030</td>
        <td class="px-2 py-1 w-[80px] text-sm"></td>
        <td class="px-2 py-1 w-[80px] text-sm"></td>
        <td class="px-2 py-1 w-[80px] text-sm">Y</td>
        <td class="px-2 py-1 w-[80px] text-sm">Y</td>    
        <td class="px-2 py-1 w-[80px] text-sm">U-2214</td>
        <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
        <td class="px-2 py-1 w-1/6 text-sm">
          <p>COMPOUND PATENT</p>
          <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
        </td>
        <td class="px-2 py-1 w-[80px] text-sm"></td>
      </tr>
   
    

          <hr>


    <!-- ==============  Table-Body 2nd=========== -->

    <tr class="border-b border-gray-300">
      <td class="px-2 py-1 w-1/6">
        <h6 class="text-blue-600 hover:underline"></h6>
        <div class="">
          <p class="text-[#2900FF] font-bold text-sm">US7326708</p>
          <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
            <img src="assets/images/components/espace.png" class="h-1" alt="Google">
          </a>
          <a href="https://patents.google.com/patent/US8080580">
            <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
          </a>
        </div>
      </td>
    
      <!-- <td class="px-2 py-1 w-1/6">
        <button class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">VIEW PATENT CLAIMS</button>
      </td> -->

      <td class="px-2 py-1 w-1/6">

      
<button (click)="openPopup2()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
VIEW PATENT CLAIMS
</button>

<div *ngIf="isPopupOpen2" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
  <div class="bg-white p-6 rounded shadow-lg w-3/4 max-h-[80vh] overflow-y-auto">
    <h2 class="text-lg font-bold">Patent Claims</h2>
  <p class="mt-2">

    Patent Information:<span style="padding-left: 800px;">  <button (click)="closePopup2()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
    </span><br> 

1. Patent Number: US7326708B2; US20050032804A1
Assignee: MERCK SHARP &amp; DOHME ([US])
Publication Date: 2008-02-05
Application Number: US10/874,992
Application Date: 2004-06-23
Equivalents: WO2005/003135A1 2005-01-13 [WO200503135]; US7326708 B2 2008-02-05 [US7326708]; US20050032804A1 2005-02-10 [US20050032804]; EP1654263 B1 2007-09-12 [EP1654263]; EP1654263 B2 2011-02-23 [EP1654263]; EP1654263 A1 2006-05-10 [EP1654263]; CA2529400 C 2007-10-09 [CA2529400]; CA2529400 A1 2005-01-13 [CA2529400]; DE602004008938 D1 2007-10-25 [DE602004008938]; DE602004008938 T2 2008-08-07 [DE602004008938]; DE602004008938 T3 2012-01-12 [DE602004008938]; JP4463768 B2 2010-05-19 [JP4463768]; JP2006516268 A 2006-06-29 [JP2006516268]; AU2004253889 B2 2008-04-24 [AU2004253889]; AU2004253889 A1 2005-01-13 [AU2004253889]; TWI347185 B 2011-08-21 [TWI347185]; TW200524610 A 2005-08-01 [TW200524610]; IS2792B 2012-08-15 [IS---2792B]; IS8183A 2005-12-15 [IS---8183]; SG118516 B 2007-11-30 [SG-118516]; SG118516 A1 2006-02-28 [SG-118516]; KR10-1016569 B1 2011-02-22 [KR101016569]; KR10-2006-0026061 A 2006-03-22 [KR20060026061]; NO335371 B1 2014-12-01 [NO-335371]; NO20060362 L 2006-03-23 [NO20060362]; MA27861 A1 2006-04-03 [MA--27861]; EA009042 B1 2007-10-26 [EA---9042]; EA200600095 A1 2006-06-30 [EA200600095]; BRPI0411726 B1 2017-12-12 [BR200411726]; BRPI0411726 B8 2021-05-25 [BR200411726]; BRPI0411726 A 2006-08-08 [BR200411726]; CN100430397 C 2008-11-05 [CN100430397C]; CN1832949 A 2006-09-13 [CN1832949]; ZA200509933 B 2006-12-27 [ZA200509933]; HK1095144 A1 2007-04-27 [HK1095144]; AT373003 T 2007-09-15 [ATE373003]; PT1654263 E 2007-11-16 [PT1654263]; HRP20070534 T3 2007-12-31 [HRP20070534]; SI1654263 T1 2007-12-31 [SI1654263T]; HRP20070534 T4 2011-06-30 [HRP20070534]; SI1654263 T2 2011-06-30 [SI1654263T]; DK1654263 T3 2008-01-07 [DK1654263T]; DK1654263 T4 2011-06-14 [DK1654263T]; PL1654263 T3 2008-01-31 [PL1654263]; PL1654263 T5 2011-07-29 [PL1654263]; ES2291907 T3 2008-03-01 [ES2291907]; ES2291907 T5 2011-05-30 [ES2291907]; KR10-1013431 B1 2011-02-14 [KR101013431]; KR10-2008-0022232 A 2008-03-10 [KR20080022232]; RS51873 B 2012-02-29 [RS--51873]; RS20050947 A 2008-04-04 [RS200500947]; VN0007037 B 2008-06-25 [VN---7037B]; IL172563 B 2008-07-08 [IL-172563]; GEP20084489 B 2008-09-25 [GE200804489]; UA86026 C2 2009-03-25 [UA--86026]; MY139595 A 2009-10-30 [MY-139595]; ME00405 B 2011-10-10 [ME----405]; MEP60208 A 2011-05-10 [ME-P60208]; JO2625B1 2011-11-01 [JO---2625]; CY1106936 T1 2012-09-26 [CY1106936]; GC0002959 B 2014-09-30 [GC---2959]; DOP2004000941A 2004-12-31 [DO200400941]; AR044705 A1 2005-09-21 [AR--44705]; MXPA05013931 A 2006-02-24 [MX2005PA013931]; CR8117A 2006-05-31 [CR---8117]; CO5660266 A2 2006-07-31 [CO5660266]; ECSP056245 A 2006-10-17 [EC200506245]; TNSN05329 A1 2007-07-10 [TN0500329]; IN5948/DELNP/2005 A 2008-05-09 [IN2005DN05948]; NZ544026 A 2008-08-29 [NZ-544026]; AR094185 A2 2015-07-15 [AR--94185]
Indian Equivalents: IN5948/DELNP/2005A; IN2005DN05948
Title: Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
By: CYPES STEPHEN HOWARD ([US]); CHEN ALEX MINHUA ([US]); FERLITA RUSSELL R ([US]); HANSEN KARL ([US]); LEE IVAN ([US]); VYDRA VICKY K ([US]); WENSLOW JR ROBERT M ([US])
Abstract: The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

Claim: 
1.  A dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8- H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural
formula I: ##STR00008## or a hydrate thereof.
 2.  The salt of claim 1 of structural formula II having the (R)-configuration at the chiral center marked with an * ##STR00009##
 3.  The salt of claim 1 of structural formula III having the (S)-configuration at the chiral center marked with an * ##STR00010##
 4.  The salt of claim 2 characterized in being a crystalline monohydrate.
 5.  The salt of claim 4 characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.42, 5.48, and 3.96 angstroms.
 6.  The salt of claim 5 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 6.30, 4.75, and 4.48 angstroms.
 7.  The salt of claim 6 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 5.85, 5.21, and 3.52 angstroms.
 8.  The salt of claim 7 further characterized by the X-ray powder diffraction pattern of FIG. 1.
 9.  The salt of claim 4 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 169.1, 120.8, and 46.5 ppm.
 10.  The salt of claim 9 further characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 159.0, 150.9, and 40.7 ppm.
 11.  The salt of claim 10 further characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 2.
 12.  The salt of claim 4 characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -64.5, -114.7, -136.3, and -146.2 ppm.
 13.  The salt of claim 12 further characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -96.5, -104.4, -106.3, and -154.5 ppm.
 14.  The salt of claim 13 further characterized by the solid-state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 3.
 15.  The salt of claim 4 characterized by the thermogravimetric analysis curve of FIG. 4.
 16.  The salt of claim 4 characterized by the differential scanning calorimetric curve of FIG. 5.
 17.  A pharmaceutical composition comprising a therapeutically effective amount of the salt according to claim 2 in association with one or more pharmaceutically acceptable carriers.
 18.  A pharmaceutical composition comprising a therapeutically effective amount of the salt according to claim 4 in association with one or more pharmaceutically acceptable carriers.
 19.  A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 2 or a hydrate thereof.
 20.  A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 4.
 21.  A process for preparing the salt of claim 2 comprising the step of contacting one equivalent of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine in an organic
solvent or aqueous organic solvent with about a one equivalent of phosphoric acid at a temperature in the range of about 25-100.degree.  C.
 22.  The process of claim 21 wherein said organic solvent is a C.sub.1-C.sub.5 linear or branched alkanol.
 23.  The phosphoric acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine prepared according to the process of claim 21.
 24.  A process for preparing the crystalline monohydrate of claim 4 comprising the steps of: (a) crystallizing the dihydrogenphosphate salt of structural formula (II): ##STR00011## at 25.degree.  C. from a mixture of isopropanol and water, such
that the water concentration is above 6.8 weight percent;  (b) recovering the resultant solid phase;  and (c) removing the solvent therefrom.
  </p>
  <!-- Close Button -->
  <button (click)="closePopup2()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
</div>
</div>


      </td>
    
      <td class="px-2 py-1 w-[80px] text-sm">2</td>
      <td class="px-2 py-1 w-[80px] text-sm">209805</td>
      <td class="px-2 py-1 w-[80px] text-sm">24-nov-2026</td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm">Y</td>
      <td class="px-2 py-1 w-[80px] text-sm">Y</td>
    
      <td class="px-2 py-1 w-[80px] text-sm">U-2214</td>
      <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
      <td class="px-2 py-1 w-1/6 text-sm">
        <p>COMPOUND SALT PATENT</p>
        <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
      </td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
    </tr>
    
          <hr>
    <!-- ==============  Table-Body 3rd=========== -->

    <tr class="border-b border-gray-300">
      <td class="px-2 py-1 w-1/6">
        <h6 class="text-blue-600 hover:underline"></h6>
        <div class="">
          <p class="text-[#2900FF] font-bold text-sm">US9439901</p>
          <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
            <img src="assets/images/components/espace.png" class="h-1" alt="Google">
          </a>
          <a href="https://patents.google.com/patent/US8080580">
            <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
          </a>
        </div>
      </td>
    
      <td class="px-2 py-1 w-1/6">

        <button (click)="openPopup3()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
          VIEW PATENT CLAIMS
          </button>
          
          <div *ngIf="isPopupOpen3" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
            <div class="bg-white p-6 rounded shadow-lg w-3/4 max-h-[80vh] overflow-y-auto">
              <h2 class="text-lg font-bold">Patent Claims</h2>
              <hr>
            <p class="mt-2"> 
              Patent Information:<span style="padding-left: 800px;">  <button (click)="closePopup3()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
              </span>
          
              <br><br>

1. Patent Number: US9439901B2; US20150065512A1
Assignee: PFIZER ([US])
Publication Date: 2016-09-13
Application Number: US14/535,556
Application Date: 2014-11-07
Equivalents: WO2011/051864A1 2011-05-05 [WO201151864]; US8669380 B2 2014-03-11 [US8669380]; US20120184486A1 2012-07-19 [US20120184486]; US9308204 B2 2016-04-12 [US9308204]; US9439901 B2 2016-09-13 [US9439901]; US9439902 B2 2016-09-13 [US9439902]; US20150065512A1 2015-03-05 [US20150065512]; US20150065513A1 2015-03-05 [US20150065513]; US20150065565A1 2015-03-05 [US20150065565]; US20130225487A1 2013-08-29 [US20130225487]; EP2496583 B1 2014-12-10 [EP2496583]; EP2496583 A1 2012-09-12 [EP2496583]; CA2777857 C 2014-12-02 [CA2777857]; CA2777857 A1 2011-05-05 [CA2777857]; JP5696156 B2 2015-04-08 [JP5696156]; JP2013509393 A 2013-03-14 [JP2013509393]; AU2010310956 B2 2014-05-08 [AU2010310956]; AU2010310956 A1 2012-06-07 [AU2010310956]; AP3099A 2015-01-31 [AP---3099]; AP2012006281 A0 2012-06-30 [AP2012006281]; KR10-1426180 B1 2014-07-31 [KR101426180]; KR10-2012-0093321 A 2012-08-22 [KR20120093321]; EA021983 B1 2015-10-30 [EA--21983]; EA201290267 A1 2012-12-28 [EA201290267]; VN0021374 B 2019-07-25 [VN--21374B]; VN32142 A 2013-01-25 [VN--32142]; ZA201203486 B 2013-07-31 [ZA201203486]; UA103416 C2 2013-10-10 [UA-103416]; PT2496583 E 2015-01-14 [PT2496583]; ES2527179 T3 2015-01-21 [ES2527179]; DK2496583 T3 2015-02-02 [DK2496583T]; SI2496583 T1 2015-02-27 [SI2496583T]; HRP20150107 T1 2015-03-13 [HRP20150107]; PL2496583 T3 2015-04-30 [PL2496583]; ME02016 B 2015-05-20 [ME---2016]; RS53827 B1 2015-06-30 [RS--53827]; IN278443 B 2016-12-30 [IN-278443]; IN4720/DELNP/2012 A 2015-12-04 [IN2012DN04720]; CY1115949 T1 2017-01-25 [CY1115949]; ECSP12011946 A 2012-07-31 [EC201211946]; CR20120289 A 2012-09-26 [CR201200289]; NZ599945 A 2014-05-30 [NZ-599945]
Indian Equivalents: IN278443B; IN-278443; IN4720/DELNP/2012A; IN2012DN04720
Title: Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
By: MASCITTI VINCENT ([US])
Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Claim: 
1.  A method for treating obesity in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a pharmaceutical
composition comprising: (i) (1S,2S,3S,4R,5S)-5-[-4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl- -6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;  (ii) a pharmaceutically acceptable excipient, diluent, or carrier and (iii) sitagliptin;  or a
pharmaceutically acceptable salt thereof.
 2.  A method for treating Type 2 diabetes in humans comprising the step of administering to a human in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising: (i)
(1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;  (ii) a pharmaceutically acceptable excipient, diluent, or carrier and (iii) sitagliptin;  or a pharmaceutically acceptable salt
thereof.
            </p>
            <!-- Close Button -->
            <button (click)="closePopup3()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
          </div>
          </div>
              
        </td>
    
      <td class="px-2 py-1 w-[80px] text-sm">2</td>
      <td class="px-2 py-1 w-[80px] text-sm">209805</td>
      <td class="px-2 py-1 w-[80px] text-sm">21-OCT-2030</td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm">Y</td>
      <td class="px-2 py-1 w-[80px] text-sm">Y</td>
    
      <td class="px-2 py-1 w-[80px] text-sm">U-2214</td>
      <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
      <td class="px-2 py-1 w-1/6 text-sm">
        <p>MOU PATENT</p>
        <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
      </td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
    </tr>
    
          <hr>

           <!-- ==============  Table-Body 4TH=========== -->

           <tr class="border-b border-gray-300">
            <td class="px-2 py-1 w-1/6">
              <h6 class="text-blue-600 hover:underline"></h6>
              <div class="">
                <p class="text-[#2900FF] font-bold text-sm">US9308204</p>
                <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
                  <img src="assets/images/components/espace.png" class="h-1" alt="Google">
                </a>
                <a href="https://patents.google.com/patent/US8080580">
                  <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
                </a>
              </div>
            </td>
          
            <td class="px-2 py-1 w-1/6">

              <button (click)="openPopup4()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
                VIEW PATENT CLAIMS
                </button>
                
                <div *ngIf="isPopupOpen4" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
                  <div class="bg-white p-6 rounded shadow-lg w-3/4 max-h-[80vh] overflow-y-auto">
                    <h2 class="text-lg font-bold">Patent Claims</h2>
                    <hr>
                  <p class="mt-2"> 

                    Patent Information:<span style="padding-left: 800px;">  <button (click)="closePopup4()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
                    </span>
                
                    <br><br>
      

1. Patent Number: US9308204B2; US20150065513A1
Assignee: PFIZER ([US])
Publication Date: 2016-04-12
Application Number: US14/535,630
Application Date: 2014-11-07
Equivalents: WO2011/051864A1 2011-05-05 [WO201151864]; US8669380 B2 2014-03-11 [US8669380]; US20120184486A1 2012-07-19 [US20120184486]; US9308204 B2 2016-04-12 [US9308204]; US9439901 B2 2016-09-13 [US9439901]; US9439902 B2 2016-09-13 [US9439902]; US20150065512A1 2015-03-05 [US20150065512]; US20150065513A1 2015-03-05 [US20150065513]; US20150065565A1 2015-03-05 [US20150065565]; US20130225487A1 2013-08-29 [US20130225487]; EP2496583 B1 2014-12-10 [EP2496583]; EP2496583 A1 2012-09-12 [EP2496583]; CA2777857 C 2014-12-02 [CA2777857]; CA2777857 A1 2011-05-05 [CA2777857]; JP5696156 B2 2015-04-08 [JP5696156]; JP2013509393 A 2013-03-14 [JP2013509393]; AU2010310956 B2 2014-05-08 [AU2010310956]; AU2010310956 A1 2012-06-07 [AU2010310956]; AP3099A 2015-01-31 [AP---3099]; AP2012006281 A0 2012-06-30 [AP2012006281]; KR10-1426180 B1 2014-07-31 [KR101426180]; KR10-2012-0093321 A 2012-08-22 [KR20120093321]; EA021983 B1 2015-10-30 [EA--21983]; EA201290267 A1 2012-12-28 [EA201290267]; VN0021374 B 2019-07-25 [VN--21374B]; VN32142 A 2013-01-25 [VN--32142]; ZA201203486 B 2013-07-31 [ZA201203486]; UA103416 C2 2013-10-10 [UA-103416]; PT2496583 E 2015-01-14 [PT2496583]; ES2527179 T3 2015-01-21 [ES2527179]; DK2496583 T3 2015-02-02 [DK2496583T]; SI2496583 T1 2015-02-27 [SI2496583T]; HRP20150107 T1 2015-03-13 [HRP20150107]; PL2496583 T3 2015-04-30 [PL2496583]; ME02016 B 2015-05-20 [ME---2016]; RS53827 B1 2015-06-30 [RS--53827]; IN278443 B 2016-12-30 [IN-278443]; IN4720/DELNP/2012 A 2015-12-04 [IN2012DN04720]; CY1115949 T1 2017-01-25 [CY1115949]; ECSP12011946 A 2012-07-31 [EC201211946]; CR20120289 A 2012-09-26 [CR201200289]; NZ599945 A 2014-05-30 [NZ-599945]
Indian Equivalents: IN278443B; IN-278443; IN4720/DELNP/2012A; IN2012DN04720
Title: Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
By: MASCITTI VINCENT ([US])
Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).

Claim: 
1.  A pharmaceutical composition comprising: (i) (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;  (ii)
a pharmaceutically acceptable excipient, diluent, or carrier;  and (iii) sitagliptin.
 2.  A pharmaceutical composition comprising: (i) (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol;  (ii) a pharmaceutically acceptable excipient, diluent, or carrier;  and
(iii) metformin.
 3.  The composition of claim 1 wherein (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol is present in a therapeutically effective amount.
 4.  The composition of claim 2 wherein (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-- 6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol is present in a therapeutically effective amount.
                    
                  </p>
                  <!-- Close Button -->
                  <button (click)="closePopup4()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
                </div>
                </div>
            </td>
          
            <td class="px-2 py-1 w-[80px] text-sm">2</td>
            <td class="px-2 py-1 w-[80px] text-sm">209805</td>
            <td class="px-2 py-1 w-[80px] text-sm">21-OCT-2030</td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm">Y</td>
            <td class="px-2 py-1 w-[80px] text-sm">Y</td>
          
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
            <td class="px-2 py-1 w-1/6 text-sm">
              <p>COMPOSITION PATENT</p>
              <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
            </td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
          </tr>
          <hr>
          

           <!-- ==============  Table-Body 5TH=========== -->

           <tr class="border-b border-gray-300">
            <td class="px-2 py-1 w-1/6">
              <h6 class="text-blue-600 hover:underline"></h6>
              <div class="">
                <p class="text-[#2900FF] font-bold text-sm">US7326708*PED</p>
                <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
                  <img src="assets/images/components/espace.png" class="h-1" alt="Google">
                </a>
                <a href="https://patents.google.com/patent/US8080580">
                  <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
                </a>
              </div>
            </td>
          
            <td class="px-2 py-1 w-1/6">

              <button (click)="openPopup5()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
                VIEW PATENT CLAIMS
                </button>
                
                <div *ngIf="isPopupOpen5" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
                  <div class="bg-white p-6 rounded shadow-lg w-3/4 max-h-[80vh] overflow-y-auto">
                    <h2 class="text-lg font-bold">Patent Claims</h2>
                    <hr>
                  <p class="mt-2"> 
                    Patent Information:
                    <span style="padding-left: 800px;">  <button (click)="closePopup5()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
                                  </span>
                                  <br><br>

1. Patent Number: US7326708B2; US20050032804A1
Assignee: MERCK SHARP &amp; DOHME ([US])
Publication Date: 2008-02-05
Application Number: US10/874,992
Application Date: 2004-06-23
Equivalents: WO2005/003135A1 2005-01-13 [WO200503135]; US7326708 B2 2008-02-05 [US7326708]; US20050032804A1 2005-02-10 [US20050032804]; EP1654263 B1 2007-09-12 [EP1654263]; EP1654263 B2 2011-02-23 [EP1654263]; EP1654263 A1 2006-05-10 [EP1654263]; CA2529400 C 2007-10-09 [CA2529400]; CA2529400 A1 2005-01-13 [CA2529400]; DE602004008938 D1 2007-10-25 [DE602004008938]; DE602004008938 T2 2008-08-07 [DE602004008938]; DE602004008938 T3 2012-01-12 [DE602004008938]; JP4463768 B2 2010-05-19 [JP4463768]; JP2006516268 A 2006-06-29 [JP2006516268]; AU2004253889 B2 2008-04-24 [AU2004253889]; AU2004253889 A1 2005-01-13 [AU2004253889]; TWI347185 B 2011-08-21 [TWI347185]; TW200524610 A 2005-08-01 [TW200524610]; IS2792B 2012-08-15 [IS---2792B]; IS8183A 2005-12-15 [IS---8183]; SG118516 B 2007-11-30 [SG-118516]; SG118516 A1 2006-02-28 [SG-118516]; KR10-1016569 B1 2011-02-22 [KR101016569]; KR10-2006-0026061 A 2006-03-22 [KR20060026061]; NO335371 B1 2014-12-01 [NO-335371]; NO20060362 L 2006-03-23 [NO20060362]; MA27861 A1 2006-04-03 [MA--27861]; EA009042 B1 2007-10-26 [EA---9042]; EA200600095 A1 2006-06-30 [EA200600095]; BRPI0411726 B1 2017-12-12 [BR200411726]; BRPI0411726 B8 2021-05-25 [BR200411726]; BRPI0411726 A 2006-08-08 [BR200411726]; CN100430397 C 2008-11-05 [CN100430397C]; CN1832949 A 2006-09-13 [CN1832949]; ZA200509933 B 2006-12-27 [ZA200509933]; HK1095144 A1 2007-04-27 [HK1095144]; AT373003 T 2007-09-15 [ATE373003]; PT1654263 E 2007-11-16 [PT1654263]; HRP20070534 T3 2007-12-31 [HRP20070534]; SI1654263 T1 2007-12-31 [SI1654263T]; HRP20070534 T4 2011-06-30 [HRP20070534]; SI1654263 T2 2011-06-30 [SI1654263T]; DK1654263 T3 2008-01-07 [DK1654263T]; DK1654263 T4 2011-06-14 [DK1654263T]; PL1654263 T3 2008-01-31 [PL1654263]; PL1654263 T5 2011-07-29 [PL1654263]; ES2291907 T3 2008-03-01 [ES2291907]; ES2291907 T5 2011-05-30 [ES2291907]; KR10-1013431 B1 2011-02-14 [KR101013431]; KR10-2008-0022232 A 2008-03-10 [KR20080022232]; RS51873 B 2012-02-29 [RS--51873]; RS20050947 A 2008-04-04 [RS200500947]; VN0007037 B 2008-06-25 [VN---7037B]; IL172563 B 2008-07-08 [IL-172563]; GEP20084489 B 2008-09-25 [GE200804489]; UA86026 C2 2009-03-25 [UA--86026]; MY139595 A 2009-10-30 [MY-139595]; ME00405 B 2011-10-10 [ME----405]; MEP60208 A 2011-05-10 [ME-P60208]; JO2625B1 2011-11-01 [JO---2625]; CY1106936 T1 2012-09-26 [CY1106936]; GC0002959 B 2014-09-30 [GC---2959]; DOP2004000941A 2004-12-31 [DO200400941]; AR044705 A1 2005-09-21 [AR--44705]; MXPA05013931 A 2006-02-24 [MX2005PA013931]; CR8117A 2006-05-31 [CR---8117]; CO5660266 A2 2006-07-31 [CO5660266]; ECSP056245 A 2006-10-17 [EC200506245]; TNSN05329 A1 2007-07-10 [TN0500329]; IN5948/DELNP/2005 A 2008-05-09 [IN2005DN05948]; NZ544026 A 2008-08-29 [NZ-544026]; AR094185 A2 2015-07-15 [AR--94185]
Indian Equivalents: IN5948/DELNP/2005A; IN2005DN05948
Title: Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
By: CYPES STEPHEN HOWARD ([US]); CHEN ALEX MINHUA ([US]); FERLITA RUSSELL R ([US]); HANSEN KARL ([US]); LEE IVAN ([US]); VYDRA VICKY K ([US]); WENSLOW JR ROBERT M ([US])
Abstract: The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

Claim: 
1.  A dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8- H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural
formula I: ##STR00008## or a hydrate thereof.
 2.  The salt of claim 1 of structural formula II having the (R)-configuration at the chiral center marked with an * ##STR00009##
 3.  The salt of claim 1 of structural formula III having the (S)-configuration at the chiral center marked with an * ##STR00010##
 4.  The salt of claim 2 characterized in being a crystalline monohydrate.
 5.  The salt of claim 4 characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.42, 5.48, and 3.96 angstroms.
 6.  The salt of claim 5 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 6.30, 4.75, and 4.48 angstroms.
 7.  The salt of claim 6 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 5.85, 5.21, and 3.52 angstroms.
 8.  The salt of claim 7 further characterized by the X-ray powder diffraction pattern of FIG. 1.
 9.  The salt of claim 4 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 169.1, 120.8, and 46.5 ppm.
 10.  The salt of claim 9 further characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 159.0, 150.9, and 40.7 ppm.
 11.  The salt of claim 10 further characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 2.
 12.  The salt of claim 4 characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -64.5, -114.7, -136.3, and -146.2 ppm.
 13.  The salt of claim 12 further characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -96.5, -104.4, -106.3, and -154.5 ppm.
 14.  The salt of claim 13 further characterized by the solid-state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 3.
 15.  The salt of claim 4 characterized by the thermogravimetric analysis curve of FIG. 4.
 16.  The salt of claim 4 characterized by the differential scanning calorimetric curve of FIG. 5.
 17.  A pharmaceutical composition comprising a therapeutically effective amount of the salt according to claim 2 in association with one or more pharmaceutically acceptable carriers.
 18.  A pharmaceutical composition comprising a therapeutically effective amount of the salt according to claim 4 in association with one or more pharmaceutically acceptable carriers.
 19.  A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 2 or a hydrate thereof.
 20.  A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 4.
 21.  A process for preparing the salt of claim 2 comprising the step of contacting one equivalent of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine in an organic
solvent or aqueous organic solvent with about a one equivalent of phosphoric acid at a temperature in the range of about 25-100.degree.  C.
 22.  The process of claim 21 wherein said organic solvent is a C.sub.1-C.sub.5 linear or branched alkanol.
 23.  The phosphoric acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine prepared according to the process of claim 21.
 24.  A process for preparing the crystalline monohydrate of claim 4 comprising the steps of: (a) crystallizing the dihydrogenphosphate salt of structural formula (II): ##STR00011## at 25.degree.  C. from a mixture of isopropanol and water, such
that the water concentration is above 6.8 weight percent;  (b) recovering the resultant solid phase;  and (c) removing the solvent therefrom.
                    
                  </p>
                  <!-- Close Button -->
                  <button (click)="closePopup5()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
                </div>
                </div>
      
            </td>
          
            <td class="px-2 py-1 w-[80px] text-sm">2</td>
            <td class="px-2 py-1 w-[80px] text-sm">209805</td>
            <td class="px-2 py-1 w-[80px] text-sm">24-may-2027</td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm">Y</td>
            <td class="px-2 py-1 w-[80px] text-sm">Y</td>
          
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-1/6 text-sm">
              <p>COMPOUND SALT PATENT</p>
              <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
            </td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
          </tr>
          
          
        </tbody>
      </table>
    </div>
    
    <div class="obexclusivitydata">

      <h4 class="obtext" style="padding: 25px 0 10px 0; font-size: 20px;">OB Exclusivity Data :</h4>

      <table class="w-full border border-gray-300">
        <thead class="bg-gray-800 text-white text-sm">
            <tr>
                <th class="px-2 py-1 text-left">Product</th>
                <th class="px-2 py-1 text-left">Product No.</th>
                <th class="px-2 py-1 text-left">Exclusive Code</th>
                <th class="px-2 py-1 text-left">Exclusive Expiration</th>
                <th class="px-2 py-1 text-left">Application No.</th>
                <th class="px-2 py-1 text-left">Application Type</th>
                <th class="px-2 py-1 text-left">Notes</th>
                <th class="px-2 py-1 text-left">Remarks</th>
                <th class="px-2 py-1 text-left">PDF, CSV, Text File downloadable format</th>
            </tr>
        </thead>
        <tbody class="bg-yellow-100">
            <tr class="border-b border-gray-300">
              <td class="px-2 py-1 w-[80px] text-sm"></td>
                <td class="px-2 py-1 w-[80px] text-sm">2</td>
                <td class="px-2 py-1 w-[80px] text-sm">M-275</td>
                <td class="px-2 py-1 w-[80px] text-sm">17-Sep-2024</td>
                <td class="px-2 py-1 w-[80px] text-sm">209805</td>
                <td class="px-2 py-1 w-[80px] text-sm">N</td>
                <td class="px-2 py-1 w-[80px] text-sm"></td>
                <td class="px-2 py-1 w-[80px] text-sm"></td>
                <td class="px-2 py-1 w-[80px] text-sm"></td>
            </tr>
        </tbody>
    </table>
    </div>

    <hr style="border: 5px solid blue;">



    <!-- ===================2nd Details=================== -->

    
  <div class="card body">
    <div class="pb-3 mb-3 px-2 rounded-lg">

      <div class="row">

        <div class="col-xl-4 col-lg-4 col-md-4 col-sm-12">

          <h5> <span style="color: blue;">2.</span> GREEN BOOK REGISTRATION NUMBER(GBRN):</h5>
          <p>10083;10313</p>

          <h5>PRODUCT NUMBER:</h5>
          <p>1</p>

          <h5>TRADE NAME:</h5>
          <p>SITAGLIPTIN</p>

          <h5>COMPANY LOGO:</h5>
          <img src="assets/images/components/Merck.png" class="image1">

          <h5>ACTIVE INGREDIENT/COMBITION:</h5>
          <p>ERTUGLIFLOZIN;SITAGLIPTIN PHOSPHATE</p>

          <h5>STRENGTH:</h5>
          <p>15MG;EQ 100MG BASE</p>

          <h5>REFERENCE LISTED DRUG(RLD):</h5>
          <p>Yes</p>

          <h5>REFERENCE STANDARD(RS):</h5>
          <p>No</p>

        </div>

        <div class="col-xl-4 col-lg-4 col-md-4 col-sm-12">

          
          <h5>DOSES FORM:</h5>
          <p>TABLET</p>

          <h5>ROUTE:</h5>
          <p>ORAL</p>

          <h5>APPLICANT:</h5>
          <p>MSD SUB MERCK</p>

          <h5>APPLICANT HOLDER FULL NAME:</h5>
          <p>MERCK SHARP AND DOHME LLC A SUB OF MERCK AND CO INC</p>

          <h5>TYPE:</h5>
          <p>Rx</p>
          <img src="assets/images/components/fda.jpg" class="image2">


        </div>

        <div class="col-xl-4 col-lg-4 col-md-4 col-sm-12">

          <h5>APPLICATION NUMBER:</h5>
          <p>209805</p>

          <h5>APPLICATION TYPE:</h5>
          <p>N</p>

          <h5>APPROVAL DATE:</h5>
          <p>19-Dec-2017</p>

        
        </div>

       </div>
      </div>

    </div>
 
     <!-- ==============  Table-Header=========== -->

     <div class="overflow-x-auto ">
      <table class="w-full border border-gray-300">
        <thead class="bg-gray-800 text-white text-xs">
          <tr>
            <th class="px-2 py-1 text-left">Patent No.</th>
            <th class="px-2 py-1 text-left">Patent Claims</th>
            <th class="px-2 py-1 text-left">Product No.</th>
            <th class="px-2 py-1 text-left">Applicant No.</th>
            <th class="px-2 py-1 text-left">Patent Expiration</th>
            <th class="px-2 py-1 text-left">Delist Requested</th>
            <th class="px-2 py-1 text-left">Jarvis RN</th>
            <th class="px-2 py-1 text-left">Drug Substance</th>
            <th class="px-2 py-1 text-left">Drug Product</th>
            <th class="px-2 py-1 text-left">Patent Use Code</th>
            <th class="px-2 py-1 text-left">Submission Date</th>
            <th class="px-2 py-1 text-left">Remarks</th>
            <th class="px-2 py-1 text-left">PDF, CSV, Text File downloadable format</th>
          </tr>
          
        </thead>
    <!-- ==============  Table-Body 1st=========== -->

    <tbody class="bg-yellow-100">
      <tr class="border-b border-gray-300">

        <td class="px-2 py-1 w-1/6">
          <h6 class="text-blue-600 hover:underline"></h6>
          <div class="">
            <p class="text-[#2900FF] font-bold text-sm">US7326708</p>
            <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
              <img src="assets/images/components/espace.png" class="h-1" alt="Google">
            </a>
            <a href="https://patents.google.com/patent/US8080580">
              <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
            </a>
          </div>
        </td>
    
        <td class="px-2 py-1 w-1/6">

          <button (click)="openPopup6()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
            VIEW PATENT CLAIMS
            </button>
            
            <div *ngIf="isPopupOpen6" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
              <div class="bg-white p-6 rounded shadow-lg w-3/4 max-h-[80vh] overflow-y-auto">
                <h2 class="text-lg font-bold">Patent Claims</h2>
                <hr>
              <p class="mt-2"> 
                Patent Information:<span style="padding-left: 800px;">  <button (click)="closePopup2()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
                </span>
                <br><br>

1. Patent Number: US7326708B2; US20050032804A1
Assignee: MERCK SHARP &amp; DOHME ([US])
Publication Date: 2008-02-05
Application Number: US10/874,992
Application Date: 2004-06-23
Equivalents: WO2005/003135A1 2005-01-13 [WO200503135]; US7326708 B2 2008-02-05 [US7326708]; US20050032804A1 2005-02-10 [US20050032804]; EP1654263 B1 2007-09-12 [EP1654263]; EP1654263 B2 2011-02-23 [EP1654263]; EP1654263 A1 2006-05-10 [EP1654263]; CA2529400 C 2007-10-09 [CA2529400]; CA2529400 A1 2005-01-13 [CA2529400]; DE602004008938 D1 2007-10-25 [DE602004008938]; DE602004008938 T2 2008-08-07 [DE602004008938]; DE602004008938 T3 2012-01-12 [DE602004008938]; JP4463768 B2 2010-05-19 [JP4463768]; JP2006516268 A 2006-06-29 [JP2006516268]; AU2004253889 B2 2008-04-24 [AU2004253889]; AU2004253889 A1 2005-01-13 [AU2004253889]; TWI347185 B 2011-08-21 [TWI347185]; TW200524610 A 2005-08-01 [TW200524610]; IS2792B 2012-08-15 [IS---2792B]; IS8183A 2005-12-15 [IS---8183]; SG118516 B 2007-11-30 [SG-118516]; SG118516 A1 2006-02-28 [SG-118516]; KR10-1016569 B1 2011-02-22 [KR101016569]; KR10-2006-0026061 A 2006-03-22 [KR20060026061]; NO335371 B1 2014-12-01 [NO-335371]; NO20060362 L 2006-03-23 [NO20060362]; MA27861 A1 2006-04-03 [MA--27861]; EA009042 B1 2007-10-26 [EA---9042]; EA200600095 A1 2006-06-30 [EA200600095]; BRPI0411726 B1 2017-12-12 [BR200411726]; BRPI0411726 B8 2021-05-25 [BR200411726]; BRPI0411726 A 2006-08-08 [BR200411726]; CN100430397 C 2008-11-05 [CN100430397C]; CN1832949 A 2006-09-13 [CN1832949]; ZA200509933 B 2006-12-27 [ZA200509933]; HK1095144 A1 2007-04-27 [HK1095144]; AT373003 T 2007-09-15 [ATE373003]; PT1654263 E 2007-11-16 [PT1654263]; HRP20070534 T3 2007-12-31 [HRP20070534]; SI1654263 T1 2007-12-31 [SI1654263T]; HRP20070534 T4 2011-06-30 [HRP20070534]; SI1654263 T2 2011-06-30 [SI1654263T]; DK1654263 T3 2008-01-07 [DK1654263T]; DK1654263 T4 2011-06-14 [DK1654263T]; PL1654263 T3 2008-01-31 [PL1654263]; PL1654263 T5 2011-07-29 [PL1654263]; ES2291907 T3 2008-03-01 [ES2291907]; ES2291907 T5 2011-05-30 [ES2291907]; KR10-1013431 B1 2011-02-14 [KR101013431]; KR10-2008-0022232 A 2008-03-10 [KR20080022232]; RS51873 B 2012-02-29 [RS--51873]; RS20050947 A 2008-04-04 [RS200500947]; VN0007037 B 2008-06-25 [VN---7037B]; IL172563 B 2008-07-08 [IL-172563]; GEP20084489 B 2008-09-25 [GE200804489]; UA86026 C2 2009-03-25 [UA--86026]; MY139595 A 2009-10-30 [MY-139595]; ME00405 B 2011-10-10 [ME----405]; MEP60208 A 2011-05-10 [ME-P60208]; JO2625B1 2011-11-01 [JO---2625]; CY1106936 T1 2012-09-26 [CY1106936]; GC0002959 B 2014-09-30 [GC---2959]; DOP2004000941A 2004-12-31 [DO200400941]; AR044705 A1 2005-09-21 [AR--44705]; MXPA05013931 A 2006-02-24 [MX2005PA013931]; CR8117A 2006-05-31 [CR---8117]; CO5660266 A2 2006-07-31 [CO5660266]; ECSP056245 A 2006-10-17 [EC200506245]; TNSN05329 A1 2007-07-10 [TN0500329]; IN5948/DELNP/2005 A 2008-05-09 [IN2005DN05948]; NZ544026 A 2008-08-29 [NZ-544026]; AR094185 A2 2015-07-15 [AR--94185]
Indian Equivalents: IN5948/DELNP/2005A; IN2005DN05948
Title: Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
By: CYPES STEPHEN HOWARD ([US]); CHEN ALEX MINHUA ([US]); FERLITA RUSSELL R ([US]); HANSEN KARL ([US]); LEE IVAN ([US]); VYDRA VICKY K ([US]); WENSLOW JR ROBERT M ([US])
Abstract: The dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine is a potent inhibitor of dipeptidyl peptidase-IV and is useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as type 2 diabetes. The invention also relates to a crystalline monohydrate of the dihydrogenphosphate salt as well as a process for its preparation, pharmaceutical compositions containing this novel form and methods of use for the treatment of diabetes, obesity, and high blood pressure.

Claim: 
1.  A dihydrogenphosphate salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8- H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine of structural
formula I: ##STR00008## or a hydrate thereof.
 2.  The salt of claim 1 of structural formula II having the (R)-configuration at the chiral center marked with an * ##STR00009##
 3.  The salt of claim 1 of structural formula III having the (S)-configuration at the chiral center marked with an * ##STR00010##
 4.  The salt of claim 2 characterized in being a crystalline monohydrate.
 5.  The salt of claim 4 characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 7.42, 5.48, and 3.96 angstroms.
 6.  The salt of claim 5 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 6.30, 4.75, and 4.48 angstroms.
 7.  The salt of claim 6 further characterized by characteristic absorption bands obtained from the X-ray powder diffraction pattern at spectral d-spacings of 5.85, 5.21, and 3.52 angstroms.
 8.  The salt of claim 7 further characterized by the X-ray powder diffraction pattern of FIG. 1.
 9.  The salt of claim 4 characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 169.1, 120.8, and 46.5 ppm.
 10.  The salt of claim 9 further characterized by a solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum showing signals at 159.0, 150.9, and 40.7 ppm.
 11.  The salt of claim 10 further characterized by the solid-state carbon-13 CPMAS nuclear magnetic resonance spectrum of FIG. 2.
 12.  The salt of claim 4 characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -64.5, -114.7, -136.3, and -146.2 ppm.
 13.  The salt of claim 12 further characterized by a solid-state fluorine-19 MAS nuclear magnetic resonance spectrum showing signals at -96.5, -104.4, -106.3, and -154.5 ppm.
 14.  The salt of claim 13 further characterized by the solid-state fluorine-19 MAS nuclear magnetic resonance spectrum of FIG. 3.
 15.  The salt of claim 4 characterized by the thermogravimetric analysis curve of FIG. 4.
 16.  The salt of claim 4 characterized by the differential scanning calorimetric curve of FIG. 5.
 17.  A pharmaceutical composition comprising a therapeutically effective amount of the salt according to claim 2 in association with one or more pharmaceutically acceptable carriers.
 18.  A pharmaceutical composition comprising a therapeutically effective amount of the salt according to claim 4 in association with one or more pharmaceutically acceptable carriers.
 19.  A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 2 or a hydrate thereof.
 20.  A method for the treatment of type 2 diabetes comprising administering to a patient in need of such treatment a therapeutically effective amount of the salt according to claim 4.
 21.  A process for preparing the salt of claim 2 comprising the step of contacting one equivalent of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine in an organic
solvent or aqueous organic solvent with about a one equivalent of phosphoric acid at a temperature in the range of about 25-100.degree.  C.
 22.  The process of claim 21 wherein said organic solvent is a C.sub.1-C.sub.5 linear or branched alkanol.
 23.  The phosphoric acid salt of (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazi- n-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine prepared according to the process of claim 21.
 24.  A process for preparing the crystalline monohydrate of claim 4 comprising the steps of: (a) crystallizing the dihydrogenphosphate salt of structural formula (II): ##STR00011## at 25.degree.  C. from a mixture of isopropanol and water, such
that the water concentration is above 6.8 weight percent;  (b) recovering the resultant solid phase;  and (c) removing the solvent therefrom.
              </p>
              <!-- Close Button -->
              <button (click)="closePopup6()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
            </div>
            </div>

        </td>
    
        <td class="px-2 py-1 w-[80px] text-sm">1</td>
        <td class="px-2 py-1 w-[80px] text-sm">209805</td>
        <td class="px-2 py-1 w-[80px] text-sm">24-nov-2026</td>
        <td class="px-2 py-1 w-[80px] text-sm"></td>
        <td class="px-2 py-1 w-[80px] text-sm"></td>
        <td class="px-2 py-1 w-[80px] text-sm">Y</td>
        <td class="px-2 py-1 w-[80px] text-sm">Y</td>
    
        <td class="px-2 py-1 w-[80px] text-sm">U-2214</td>
        <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
        <td class="px-2 py-1 w-1/6 text-sm">
          <p>COMPOUND SALT PATENT</p>
          <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
        </td>
        <td class="px-2 py-1 w-[80px] text-sm"></td>
      </tr>
   
    

          <hr>


    <!-- ==============  Table-Body 2nd=========== -->

    <tr class="border-b border-gray-300">
      <td class="px-2 py-1 w-1/6">
        <h6 class="text-blue-600 hover:underline"></h6>
        <div class="">
          <p class="text-[#2900FF] font-bold text-sm">US8080580</p>
          <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
            <img src="assets/images/components/espace.png" class="h-1" alt="Google">
          </a>
          <a href="https://patents.google.com/patent/US8080580">
            <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
          </a>
        </div>
      </td>
    
      <td class="px-2 py-1 w-1/6">

        <button (click)="openPopup7()" class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">
          VIEW PATENT CLAIMS
          </button>
          
          <div *ngIf="isPopupOpen7" class="fixed inset-0 flex items-center justify-center bg-black bg-opacity-50">
            <div class="bg-white p-6 rounded shadow-lg w-3/4 max-h-[80vh] overflow-y-auto">
              <h2 class="text-lg font-bold">Patent Claims</h2>
              <hr>
            <p class="mt-2"> 
              Patent Information:
              <span style="padding-left: 800px;">  <button (click)="closePopup2()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
                            </span>
                            <br><br>
                            
              

 </p>
            <!-- Close Button -->
            <button (click)="closePopup7()" class="mt-4 bg-red-500 text-white px-4 py-2 rounded">Close</button>
          </div>
          </div>
      </td>
    
      <td class="px-2 py-1 w-[80px] text-sm">1</td>
      <td class="px-2 py-1 w-[80px] text-sm">209805</td>
      <td class="px-2 py-1 w-[80px] text-sm">13-JULY-2030</td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm">Y</td>
      <td class="px-2 py-1 w-[80px] text-sm">Y</td>
    
      <td class="px-2 py-1 w-[80px] text-sm">U-2214</td>
      <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
      <td class="px-2 py-1 w-1/6 text-sm">
        <p>COMPOUND  PATENT</p>
        <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
      </td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
    </tr>
    
          <hr>
    <!-- ==============  Table-Body 3rd=========== -->

    <tr class="border-b border-gray-300">
      <td class="px-2 py-1 w-1/6">
        <h6 class="text-blue-600 hover:underline"></h6>
        <div class="">
          <p class="text-[#2900FF] font-bold text-sm">US9439901</p>
          <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
            <img src="assets/images/components/espace.png" class="h-1" alt="Google">
          </a>
          <a href="https://patents.google.com/patent/US8080580">
            <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
          </a>
        </div>
      </td>
    
      <td class="px-2 py-1 w-1/6">
        <button class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">VIEW PATENT CLAIMS</button>
      </td>
    
      <td class="px-2 py-1 w-[80px] text-sm">1</td>
      <td class="px-2 py-1 w-[80px] text-sm">209805</td>
      <td class="px-2 py-1 w-[80px] text-sm">21-OCT-2030</td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
    
      <td class="px-2 py-1 w-[80px] text-sm">U-2214</td>
      <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
      <td class="px-2 py-1 w-1/6 text-sm">
        <p>MOU PATENT</p>
        <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
      </td>
      <td class="px-2 py-1 w-[80px] text-sm"></td>
    </tr>
    
          <hr>

           <!-- ==============  Table-Body 4TH=========== -->

           <tr class="border-b border-gray-300">
            <td class="px-2 py-1 w-1/6">
              <h6 class="text-blue-600 hover:underline"></h6>
              <div class="">
                <p class="text-[#2900FF] font-bold text-sm">US9308204</p>
                <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
                  <img src="assets/images/components/espace.png" class="h-1" alt="Google">
                </a>
                <a href="https://patents.google.com/patent/US8080580">
                  <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
                </a>
              </div>
            </td>
          
            <td class="px-2 py-1 w-1/6">
              <button class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">VIEW PATENT CLAIMS</button>
            </td>
          
            <td class="px-2 py-1 w-[80px] text-sm">1</td>
            <td class="px-2 py-1 w-[80px] text-sm">209805</td>
            <td class="px-2 py-1 w-[80px] text-sm">21-OCT-2030</td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm">Y</td>
          
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm">16-jan-2018</td>
            <td class="px-2 py-1 w-1/6 text-sm">
              <p>COMPOSITION PATENT</p>
              <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
            </td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
          </tr>
          <hr>
          

           <!-- ==============  Table-Body 5TH=========== -->

           <tr class="border-b border-gray-300">
            <td class="px-2 py-1 w-1/6">
              <h6 class="text-blue-600 hover:underline"></h6>
              <div class="">
                <p class="text-[#2900FF] font-bold text-sm">US7326708*PED</p>
                <a href="https://worldwide.espacenet.com/patent/search/family/041208284/publication/US8080580B2?q=US8080580">
                  <img src="assets/images/components/espace.png" class="h-1" alt="Google">
                </a>
                <a href="https://patents.google.com/patent/US8080580">
                  <img src="assets/images/components/GooglePatents.png" class="h-2" alt="Espace">
                </a>
              </div>
            </td>
          
            <td class="px-2 py-1 w-1/6">
              <button class="bg-yellow-600 text-white px-3 py-1 rounded hover:bg-yellow-700 text-sm">VIEW PATENT CLAIMS</button>
            </td>
          
            <td class="px-2 py-1 w-[80px] text-sm">1</td>
            <td class="px-2 py-1 w-[80px] text-sm">209805</td>
            <td class="px-2 py-1 w-[80px] text-sm">24-may-2027</td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
          
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
            <td class="px-2 py-1 w-1/6 text-sm">
              <p>COMPOUND SALT PATENT</p>
              <button class="bg-yellow-500 text-white px-2 py-1 rounded hover:bg-yellow-600 text-sm">READ MORE</button>
            </td>
            <td class="px-2 py-1 w-[80px] text-sm"></td>
          </tr>
          
          
        </tbody>
      </table>
    </div>
    
    <div class="obexclusivitydata">

      <h4 class="obtext" style="padding: 25px 0 10px 0; font-size: 20px;">OB Exclusivity Data :</h4>

      <table class="w-full border border-gray-300">
        <thead class="bg-gray-800 text-white text-sm">
            <tr>
                <th class="px-2 py-1 text-left">Product</th>
                <th class="px-2 py-1 text-left">Product No.</th>
                <th class="px-2 py-1 text-left">Exclusive Code</th>
                <th class="px-2 py-1 text-left">Exclusive Expiration</th>
                <th class="px-2 py-1 text-left">Application No.</th>
                <th class="px-2 py-1 text-left">Application Type</th>
                <th class="px-2 py-1 text-left">Notes</th>
                <th class="px-2 py-1 text-left">Remarks</th>
                <th class="px-2 py-1 text-left">PDF, CSV, Text File downloadable format</th>
            </tr>
        </thead>
        <tbody class="bg-yellow-100">
            <tr class="border-b border-gray-300">
              <td class="px-2 py-1 w-[80px] text-sm"></td>
                <td class="px-2 py-1 w-[80px] text-sm">1</td>
                <td class="px-2 py-1 w-[80px] text-sm">M-275</td>
                <td class="px-2 py-1 w-[80px] text-sm">17-Sep-2024</td>
                <td class="px-2 py-1 w-[80px] text-sm">209805</td>
                <td class="px-2 py-1 w-[80px] text-sm">N</td>
                <td class="px-2 py-1 w-[80px] text-sm"></td>
                <td class="px-2 py-1 w-[80px] text-sm"></td>
                <td class="px-2 py-1 w-[80px] text-sm"></td>
            </tr>
        </tbody>
    </table>
    </div>

    <hr style="border: 5px solid blue;">
